Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis

References

• ParsonsDWJonesSZhangXAn integrated genomic analysis of human glioblastoma multiformeScience200832158971807181218772396
   PubMed Web of Science ®Google Scholar
• PeereboomDMShepardDRAhluwaliaMSPhase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiformeJ Neurooncol2010981939919960228
   PubMed Web of Science ®Google Scholar
• JoshiADLoilomeWSiuIMTylerBGalliaGLRigginsGJEvaluation of tyrosine kinase inhibitor combinations for glioblastoma therapyPloS One2012710e4437223056179
   PubMed Web of Science ®Google Scholar
• StuppRMasonWPvan den BentMJRadiotherapy plus concomitant and adjuvant temozolomide for glioblastomaN Engl J Med20053521098799615758009
   PubMed Web of Science ®Google Scholar
• StewartLAChemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trialsLancet200235993111011101811937180
   PubMed Web of Science ®Google Scholar
• TortoraGBiancoRDanieleGOvercoming resistance to molecularly targeted anticancer therapies: rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignanciesDrug Resist Updat20071038110017482503
   PubMed Web of Science ®Google Scholar
• GuntherWPawlakEDamascenoRArnoldHTerzisAJTemozolomide induces apoptosis and ence in glioma cells cultured as multicellular spheroidsBr J Cancer200388346346912569392
   PubMed Web of Science ®Google Scholar
• StuppRHegiMEMasonWPEffects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialLancet Oncol200910545946619269895
   PubMed Web of Science ®Google Scholar
• CohenALColmanHGlioma biology and molecular markersCancer Treat Res2015163153025468223
   PubMedGoogle Scholar
• AlentornADuran-PenaAPingleSCPiccioniDEIdbaihAKesariSMolecular profiling of gliomas: potential therapeutic implicationsExpert Rev Anticancer Ther201515895596226118895
   PubMed Web of Science ®Google Scholar
• TaylorTEFurnariFBCaveneeWKTargeting EGFR for treatment of glioblastoma: molecular basis to overcome resistanceCurr Cancer Drug Targets201212319720922268382
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTETomczakPSunitinib versus interferon alfa in metastatic renal-cell carcinomaN Engl J Med2007356211512417215529
   PubMed Web of Science ®Google Scholar
• KrakstadCChekenyaMSurvival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeuticsMol Cancer2010913520515495
   PubMed Web of Science ®Google Scholar
• ReardonDAWenPYTherapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agentsOncologist200611215216416476836
   PubMed Web of Science ®Google Scholar
• AndreFDelucheEBonnefoiHBevacizumab: the phoenix of breast oncology?Lancet Oncol201516660060125975636
   PubMed Web of Science ®Google Scholar
• SathornsumeteeSDesjardinsAVredenburghJJPhase II trial of bevacizumab and erlotinib in patients with recurrent malignant gliomaNeuro Ooncol2010121213001310
   PubMed Web of Science ®Google Scholar
• HillerdalVEssandMChimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancerBioDrugs2015292758925859858
   PubMed Web of Science ®Google Scholar
• LeavyOImmunotherapy: a triple blow for cancerNat Rev Cancer2015155258259
   Web of Science ®Google Scholar
• WhitesideTLDemariaSRodriguez-RuizMEZarourHMMeleroIEmerging opportunities and challenges in cancer immunotherapyClin Cancer Res20162281845185527084738
   PubMed Web of Science ®Google Scholar
• LeeSJKangWYYoonYNatural killer (NK) cells inhibit systemic metastasis of glioblastoma cells and have therapeutic effects against glioblastomas in the brainBMC Cancer2015151101126704632
   PubMed Web of Science ®Google Scholar
• JollerNHaflerJPBrynedalBCutting edge: TIGIT has T cell-intrinsic inhibitory functionsJ Immunol201118631338134221199897
   PubMed Web of Science ®Google Scholar
• DriessensGKlineJGajewskiTFCostimulatory and coinhibitory receptors in anti-tumor immunityImmunol Rev2009229112614419426219
   PubMed Web of Science ®Google Scholar
• JacksonCRuzevickJPhallenJBelcaidZLimMChallenges in immunotherapy presented by the glioblastoma multiforme microenvironmentClin Dev Immunol2011201173241322190972
   PubMedGoogle Scholar
• SaikaliSAvrilTColletBExpression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapyJ Neurooncol200781213914817004103
   PubMed Web of Science ®Google Scholar
• GranucciFLutzMBZanoniIThe nature of activatory and tolerogenic dendritic cell-derived signal 2Front Immunol201454224567734
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• MargolinKErnstoffMSHamidOIpilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trialLancet Oncol201213545946522456429
   PubMed Web of Science ®Google Scholar
• KahlonKSBrownCCooperLJRaubitschekAFormanSJJensenMCSpecific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cellsCancer Res200464249160916615604287
   PubMed Web of Science ®Google Scholar
• YuJSLiuGYingHYongWHBlackKLWheelerCJVaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant gliomaCancer Res200464144973497915256471
   PubMed Web of Science ®Google Scholar
• XuXStockhammerFSchmittMCellular-based immunotherapies for patients with glioblastoma multiformeClin Dev Immunol2012201276421322474481
   PubMedGoogle Scholar
• YamanakaRHommaJYajimaNClinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trialClin Cancer Res200511114160416715930352
   PubMed Web of Science ®Google Scholar
• WheelerCJBlackKLLiuGVaccination elicits correlated immune and clinical responses in glioblastoma multiforme patientsCancer Res200868145955596418632651
   PubMed Web of Science ®Google Scholar
• WehnerRLobelBBornhauserMReciprocal activating interaction between 6-sulfo LacNAc+ dendritic cells and NK cellsInt J Cancer2009124235836618942710
   PubMed Web of Science ®Google Scholar
• CaoJXZhangXYLiuJLClinical efficacy of tumor antigen-pulsed DC treatment for high-grade glioma patients: evidence from a meta-analysisPloS One201499e10717325215607
   PubMed Web of Science ®Google Scholar
• Stark-VanceVBevacizumab and CPT-11 in the treatment of relapsed malignant gliomaNeuro Oncol20057369 Abstract 342
   Web of Science ®Google Scholar
• PradosMDLambornKYungWKA phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium studyNeuro Oncol20068218919316533878
   PubMed Web of Science ®Google Scholar
• PradosMDYungWKJaeckleKAPhase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium studyNeuro Oncol200461445414769140
   PubMed Web of Science ®Google Scholar
• VredenburghJJDesjardinsAHerndonJE2ndPhase II trial of bevacizumab and irinotecan in recurrent malignant gliomaClin Cancer Res20071341253125917317837
   PubMed Web of Science ®Google Scholar
• ChenWDelaloyeSSilvermanDHPredicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot studyJ Clin Oncol200725304714472117947718
   PubMed Web of Science ®Google Scholar
• ZhangGHuangSWangZA meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiformeJ Clin Neurosci201219121636164023047061
   PubMed Web of Science ®Google Scholar
• WongETGautamSMalchowCLunMPanEBremSBevacizumab for recurrent glioblastoma multiforme: a meta-analysisJ Natl Compr Canc Netw20119440340721464145
   PubMed Web of Science ®Google Scholar
• DesjardinsAReardonDAHerndonJE2ndBevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomasClin Cancer Res200814217068707318981004
   PubMed Web of Science ®Google Scholar
• FriedmanHSPradosMDWenPYBevacizumab alone and in combination with irinotecan in recurrent glioblastomaJ Clin Oncol200927284733474019720927
   PubMed Web of Science ®Google Scholar
• KreislTNKimLMooreKPhase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastomaJ Clin Oncol200927574074519114704
   PubMed Web of Science ®Google Scholar
• VredenburghJJDesjardinsAHerndonJE2ndBevacizumab plus irinotecan in recurrent glioblastoma multiformeJ Clin Oncol200725304722472917947719
   PubMed Web of Science ®Google Scholar
• YamanakaRAbeTYajimaNVaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trialBr J Cancer20038971172117914520441
   PubMed Web of Science ®Google Scholar
• BoksteinFShpigelSBlumenthalDTTreatment with bevacizumab and irinotecan for recurrent high-grade glial tumorsCancer2008112102267227318327820
   PubMed Web of Science ®Google Scholar
• PoulsenHSGrunnetKSorensenMBevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumoursActa Oncol2009481525819031176
   PubMed Web of Science ®Google Scholar
• PrinsRMSotoHKonkankitVGene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapyClin Cancer Res20111761603161521135147
   PubMed Web of Science ®Google Scholar
• ChangCNHuangYCYangDMA phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant gliomaJ Clin Neurosci20111881048105421715171
   PubMed Web of Science ®Google Scholar
• SakaiKShimodairaSMaejimaSDendritic cell-based immunotherapy targeting Wilms’ tumor 1 in patients with recurrent malignant gliomaJ Neurosurg2015123498999726252465
   PubMed Web of Science ®Google Scholar
• IwamiKShimatoSOhnoMPeptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor alpha2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 alleleCytotherapy201214673374222424217
   PubMed Web of Science ®Google Scholar
• NaritaYBevacizumab for glioblastomaTher Clin Risk Manag2015111759176526664126
   PubMed Web of Science ®Google Scholar
• GilbertMRDignamJJArmstrongTSA randomized trial of bevacizumab for newly diagnosed glioblastomaN Engl J Med2014370869970824552317
   PubMed Web of Science ®Google Scholar
• WangYXingDZhaoMWangJYangYThe role of a single angiogenesis inhibitor in the treatment of recurrent glioblastoma multiforme: a meta-analysis and systematic reviewPloS One2016113e015217027007828
   PubMed Web of Science ®Google Scholar
• ChinotOLWickWMasonWBevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastomaN Engl J Med2014370870972224552318
   PubMed Web of Science ®Google Scholar
• van LindeMEVerhoeffJJRichelDJBevacizumab in combination with radiotherapy and temozolomide for patients with newly diagnosed glioblastoma multiformeOncologist201520210710825582142
   PubMed Web of Science ®Google Scholar
• WeathersSPGilbertMRCurrent challenges in designing GBM trials for immunotherapyJ Neurooncol2015123333133725577401
   PubMed Web of Science ®Google Scholar
• RolleCESenguptaSLesniakMSChallenges in clinical design of immunotherapy trials for malignant gliomaNeurosurg Clin N Am201021120121419944979
   PubMed Web of Science ®Google Scholar
• LiebeltBDFinocchiaroGHeimbergerABPrinciples of immunotherapyHandb Clin Neurol201613416318126948354
   PubMedGoogle Scholar
• BinderDCDavisAAWainwrightDAImmunotherapy for cancer in the central nervous system: current and future directionsOncoimmunology201652e108202727057463
   PubMed Web of Science ®Google Scholar
• GargADVandenberkLKoksCDendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade gliomaSci Transl Med20168328328ra327
   Web of Science ®Google Scholar